Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical is a single product company with its flagship product, the RECELL system, showing strong potential for growth and adoption in the US market, driven by its innovative technology and expanded indication for soft-tissue reconstruction. Although financials and revenue from international markets are currently modest, the company's strategic focus on the US and potential updates from ongoing studies and medical conferences indicate a positive outlook for future growth and adoption. However, as with any healthcare company, there are inherent risks, including clinical/regulatory, financial, commercial, legal, and market share risks, that should be considered by potential investors.

Bears say

AVITA Medical is highly dependent on its single product, the RECELL system, which is only approved in the US and is not actively marketed in other territories. Though the company has strong relationships with key organizations, such as BARDA, the revenue generated from these partnerships is limited and uncertain, indicating minimal near-term financial impact. The success of AVITA depends on its ability to translate clinical data and momentum into sustained revenue growth and commercial adoption, which is yet to be seen and poses a significant risk for the company's financial future.

RCEL has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Strong Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Strong Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.